Skip to NavigationSkip to content

Teva's EpiPen generic retails for same price as Mylan's own

Published on 28/11/18 at 11:34am

Israeli generics firm Teva has revealed the price tag of its generic version of Mylan’s EpiPen epinephrine auto-injector, and, at $300 wholesale for a pack of two, it comes in at exactly the same point as Mylan’s own long-anticipated generic version.

The announcement means that patients have two alternative options for the therapy, which both come in at less than half the cost of the branded product.

The recent shortage of EpiPens, which Mylan blames on manufacturing issues at a plant run by Pfizer, has compounded the need for cheaper, generic versions.  With the launch of the Teva’s product, it is now available in the US, albeit with limited supply; the company appeared unable to confirm how many it had released into the market, noting that the product is complex in nature and manufacturing only began in August following its FDA approval.  

According to Teva, additional supply is inbound next year, as well as a generic version of Mylan’s EpiPen Jr, which carries a lower dose.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches